- Conditions
- Systemic Lupus Erythematosus
- Interventions
- BI 3000202, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 405 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 30
- States / cities
- Beverly Hills, California • La Palma, California • San Diego, California + 27 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1345–1368
of 22,199
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Diabetic Nephropathy
- Interventions
- SPP301
- Drug
- Lead sponsor
- Speedel Pharma Ltd.
- Industry
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 2,364 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Greenville, North Carolina
- Conditions
- Epilepsy
- Interventions
- TAK-935, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Cancer, Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma), Physical Activity, Physical Activity Behavior, Cancer (With or Without Metastasis), Cancer - Chronic Lymphocytic Leukemia, Cancer - Ovarian
- Interventions
- Virtually Supervised Exercise Sessions, Asynchronous Group
- Behavioral
- Lead sponsor
- Colorado State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Fort Collins, Colorado
- Conditions
- Implant Complication
- Interventions
- Immediate loading of maxillary implant overdenture, Delayed loading of maxillary implant overdenture
- Procedure
- Lead sponsor
- Case Western Reserve University
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2028
- U.S. locations
- 2
- States / cities
- Cleveland, Ohio • Morgantown, West Virginia
- Conditions
- Pain, Postoperative
- Interventions
- CBD Oral Disintegrating Tablet (ODT), Placebo ODT
- Drug · Other
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Myopia
- Interventions
- etafilcon A
- Device
- Lead sponsor
- Johnson & Johnson Vision Care, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 7
- States / cities
- Jacksonville, Florida • Honolulu, Hawaii • Kahului, Hawaii + 4 more
- Conditions
- End Stage Renal Disease
- Interventions
- the SPIRIT intervention
- Behavioral
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 210 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Delirium, Postoperative Cognitive Dysfunction
- Interventions
- Lumosity
- Device
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 60 Years to 90 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Acquired Bleeding Disorder, Bleeding During/Following Surgery
- Interventions
- standard therapy, placebo, activated recombinant human factor VII
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 7
- States / cities
- Little Rock, Arkansas • Duarte, California • Baltimore, Maryland + 4 more
- Conditions
- Healthy Adult Women
- Interventions
- 1-Fermented Dairy Product (test), 2-Milk-based non-fermented dairy product(control)
- Other
- Lead sponsor
- Danone Global Research & Innovation Center
- Industry
- Eligibility
- 18 Years to 60 Years · Female only
- Enrollment
- 51 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)
- Interventions
- Vayarin®, Placebo
- Other
- Lead sponsor
- Enzymotec
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 171 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 4
- States / cities
- Marietta, Georgia • Mount Kisco, New York • New York, New York
- Conditions
- Alzheimer Disease
- Interventions
- TACAD, Alzheimer's Association website
- Behavioral
- Lead sponsor
- University of Texas at Austin
- Other
- Eligibility
- 40 Years to 65 Years · Female only
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Active Rheumatoid Arthritis
- Interventions
- SBI-087, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 20
- States / cities
- Paradise Valley, Arizona • Palm Desert, California • Santa Monica, California + 17 more
- Conditions
- Facial Neuropathy
- Interventions
- Lamotrigine, Placebo (for Lamotrigine)
- Drug
- Lead sponsor
- Pain and Analgesia Imaging and Neuroscience Group
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Belmont, Massachusetts
- Conditions
- Major Depressive Disorder
- Interventions
- Aripiprazole 5mg, Aripiprazole 2mg, Placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Chronic Kidney Disease, Type 2 Diabetes
- Interventions
- Finerenone, Semaglutide, Lotensin, Capoten, Enalapril, Monopril, Lisinopril, Univasc, Aceon, Accupril, Altace, Mavik, Edarbi, Atacand, Avapro, Cozaar, Benicar, Micardis, Diovan, Invokana, Farxiga, Jardiance, Ertugliflozin, Brenzavvy, Sotagliflozin
- Drug
- Lead sponsor
- Baylor Research Institute
- Other
- Eligibility
- 18 Years to 84 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Temple, Texas
- Conditions
- Colitis Ulcerative
- Interventions
- SAR443122, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 187 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 14
- States / cities
- Lancaster, California • Atlanta, Georgia • Evanston, Illinois + 10 more
- Conditions
- Diabetes Mellitus
- Interventions
- Glucose to Goal, Usual Care
- Other
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 4,994 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Friedreich Ataxia
- Interventions
- Idebenone
- Drug
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- 9 Years to 17 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- olodaterol, tiotropium, placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 809 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 20
- States / cities
- Jasper, Alabama • Stamford, Connecticut • Clearwater, Florida + 17 more
- Conditions
- Dravet Syndrome
- Interventions
- ZX008 (Fenfluramine Hydrochloride), Matching Placebo
- Drug
- Lead sponsor
- Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
- Industry
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 5
- States / cities
- San Francisco, California • Aurora, Colorado • Chicago, Illinois + 2 more
- Conditions
- Herpes Simplex, HIV Infections, Herpes Genitalis
- Interventions
- Valacyclovir hydrochloride
- Drug
- Lead sponsor
- Glaxo Wellcome
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 20
- States / cities
- Berkeley, California • Beverly Hills, California • Los Angeles, California + 17 more
- Conditions
- Schizo-Affective Type of Psychosis, Schizophrenia
- Interventions
- Psychosis and cognitive assessments, Physical and neuro-cognitive evaluations, Safety labs and electrocardiogram, Ocrelizumab infusion
- Behavioral · Diagnostic Test · Biological
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas